Trust Company’s Krystal Biotech KRYS Stock Holding History

Trust Company’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$743	Hold	2	–	–	﹤0.01%	658
2026 Q1	$517	Hold	2	–	–	﹤0.01%	701
2025 Q4	$493	Buy	+2	New	+$421	﹤0.01%	695

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Trust Company's KRYS Position: Q2 2026 in Review

Trust Company held its Krystal Biotech (KRYS) position steady in Q2 2026 at 2 shares worth $743. The position accounts for ﹤0.01% of the portfolio, ranked #658.

Trust Company first reported a position in KRYS in Q4 2025 and has held it in 3 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Trust Company held 2 shares of Krystal Biotech worth $743 as of Q2 2026.
Trust Company left its Krystal Biotech share count unchanged in Q2 2026.
Krystal Biotech made up ﹤0.01% of Trust Company's portfolio in Q2 2026, its #658 holding.
Trust Company first reported a position in Krystal Biotech in Q4 2025 and has held it in 3 quarters since.
424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Trust Company's 13F filing for Q2 2026, filed 10 Jul 2026.